Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials

• Documented COPD diagnosis for ≥ 12 months

• History of frequent exacerbations, defined as having had 2 or more moderate or severe COPD exacerbations within 12 months prior to screening

• Post-bronchodilator FEV1 ≥ 20% and \< 80% of predicted at screening

• Post-bronchodilator FEV1/FVC \< 0.70 at screening

• Modified Medical Research Council (dyspnea scale) (mMRC) score ≥ 2

• Current tobacco smoker or former smoker with a history of smoking ≥ 10 pack-years

• On optimized COPD maintenance therapy as defined below for ≥ 12 months prior to screening, and stable on current therapy for at least 4 weeks prior to screening: Inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA), Long-acting muscarinic antagonist (LAMA) plus LABA, ICS plus LAMA plus LABA

• Chest X-ray or computed tomography (CT) scan within 6 months prior to screening or chest X-ray during the screening period that confirms the absence of clinically significant lung disease besides COPD